摘要 |
This invention relates to substituted pyridopyrirnidinones of general formula (I): <CHEM> wherein n is 0 to 3; R<1> and R<2> are, independently, H, C1-C6alkyl, hydroxy(C1-C6alkyl), formyl, carbonyl(C1-C6alkyl), carboxy, or carboxy(C1-C6alkyl); R<3> and R<4> are, independently, H, C1-C6alkyl, or hydroxy; R<3a> and R<4a> are H, or one of -CR<3>R<3a> and -CR<4>R<4a> is a carbonyl group; with the proviso that at least one of the groups R<1> and R<2> must be hydroxy(C1-C6alkyl), formyl, carbonyl(C1-C6alkyl), carboxy, or carboxy(C1-C6alkyl); or one of R<3> and R<4> must be hydroxy; or one of -CR<3>R<3a> and -CR<4>R<4a>must be a carbonyl group;; Ar<1> is <CHEM> wherein W is H, C1-C6alkyl, halogen, hydroxy, or C1-C6alkoxy; Ar<2> is <CHEM> wherein X is CO2H, CN, or <CHEM> wherein R<5> is H, CH3, tert-butyl, tri-n-butylstannyl, or triphenylmethyl; or a tautomer of said compound, or a pharmaceutically acceptable salt of said compound or tautomer. The compounds of Formula I are useful for treating hypertension and congestive heart failure. Also disclosed are pharmaceutical compositions containing compounds of Formula I and a pharmaceutically acceptable carrier and methods for production of the compounds of Formula I. |